Neuronetics (STIM) Cash & Equivalents (2017 - 2026)

Neuronetics (STIM) has 10 years of Cash & Equivalents data on file, last reported at $5.8 million in Q1 2026.

• On a quarterly basis, Cash & Equivalents rose 475.0% year-over-year to $5.8 million in Q1 2026; TTM through Mar 2026 was $5.8 million, a 475.0% increase from a year earlier, with the FY2025 full-year figure at $6.0 million, up 500.0% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $5.8 million, down from $6.0 million in the prior quarter.
• Over the last five years, Cash & Equivalents for STIM reached as high as $80.8 million in Q1 2022 and fell as low as $1.0 million in Q4 2024.
• Historically, Cash & Equivalents has averaged $37.4 million across 5 years, with a median of $42.6 million in 2024.
• Across the five-year window, Cash & Equivalents plunged 98.32% in 2024 and soared 500.0% in 2025, its largest moves.
• Year by year, Cash & Equivalents stood at $70.3 million in 2022, then slipped by 15.16% to $59.7 million in 2023, then plunged by 98.32% to $1.0 million in 2024, then surged by 500.0% to $6.0 million in 2025, then decreased by 4.17% to $5.8 million in 2026.
• Per Business Quant data, the three most recent Cash & Equivalents figures were $5.8 million in Q1 2026, $6.0 million in Q4 2025, and $6.5 million in Q3 2025.